Status:
COMPLETED
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Carcinoma, Small Cell
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This clinical trial involves the administration of the chemotherapeutic medication vinflunine. Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung c...
Detailed Description
Eligible patients will receive vinflunine as a 15-20 minute intravenous (IV)infusion once every three weeks (21 days). This three week treatment period is called a cycle. Patients whose cancer has not...
Eligibility Criteria
Inclusion
- Small cell lung cancer with progression after one previous chemotherapy or chemotherapy/radiation therapy regimen
- Measurable or evaluable disease
- Able to perform activities of daily living with minimal assistance
- Adequate hematological, liver, and kidney function
- Must give written informed consent prior to entry
Exclusion
- CNS involvement
- Serious active infection or underlying medical condition
- Significant history of uncontrolled cardiac disease
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00284154
Start Date
January 1 2006
End Date
November 1 2009
Last Update
March 13 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida Cancer Specialists
Fort Myers, Florida, United States, 33901
2
Oncology Hematology Care
Cincinnati, Ohio, United States, 45242
3
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023